Stuart E. Seropian

Dr. Stuart E. Seropian


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2012 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
BOBilal Omer
Bilal Omer
NKNina S. Kadan‐Lottick
Nina S. Kadan‐Lottick
KRKenneth B. Roberts
Kenneth B. Roberts
RWRong Wang
Rong Wang
CDCarolyn Demsky
Carolyn Demsky
XMXiaomei Ma
Xiaomei Ma
To evaluate the impact of reduced radiation and combined modality therapy (CMT) in the treatment of Hodgkin lymphoma, we assessed the risk of second malignant neoplasms (SMNs) in patients who received extended‐field radiotherapy only and patients who underwent CMT. Among 404 patients treated at Yale during 1970–2004, the risk of solid SMNs was elevated in the radiotherapy only group (n = 198, median follow‐up = 21·1 years) compared to the general population, with a standardized incidence ratio (SIR) of 1·85 [95% confidence interval (CI): 1·17–2·78]. No increase was observed in the CMT group (n = 206, median follow‐up = 14·3 years), although potential differences in SMN risk were indicated across the age spectrum in subgroup analysis. Patients who received mustard‐containing regimens had increased risks for haematological SMNs (SIR = 8·74) and all SMNs (SIR = 1·85). When the analysis was stratified by age at diagnosis, children (0–20 years) had a significantly higher risk of SMNs (SIR = 5·24, 95% CI: 2·26–10·33), regardless of the treatment received. These findings suggest that recent treatment options utilizing lower dose radiation and less intense alkylator chemotherapy might be associated with lower incidences of SMNs among adults but not necessarily children.

1 October 2003 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
SSStuart E. Seropian
Stuart E. Seropian
EBE Bahceci
E Bahceci
DCD L Cooper
D L Cooper

24 March 2015 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
MCMichael Cecchini
Michael Cecchini
MSMario Sznol
Mario Sznol
SSStuart E. Seropian
Stuart E. Seropian
Metastatic melanoma is frequently treated with immune activating therapy, which poses a theoretical risk of inducing graft versus host disease (GVHD) in those who have received allogeneic stem cell transplantation. The literature reporting the safety of immunotherapy in post transplant patients is limited. We report two patients with metastatic melanoma who received treatment with immunotherapy after allogeneic stem cell transplantation that did not result in GVHD.

28 April 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JVJennifer VanOudenhove
Jennifer VanOudenhove
YLYuxin Liu
Yuxin Liu
RNRaman Nelakanti
Raman Nelakanti
DKDongjoo Kim
Dongjoo Kim
EBEmma Busarello
Emma Busarello
SHStephanie Halene
Stephanie Halene
During the COVID-19 pandemic, hematopoietic stem cell transplant (HSCT) recipients had elevated mortality rates from SARS-CoV-2 infection, ranging between 10–40%. SARS-CoV-2 mRNA vaccines are important tools in preventing severe disease, yet their efficacy post-transplant remains unclear, especially in patients subjected to myeloablative chemotherapy and immunosuppression. We evaluated humoral and adaptive immune responses to the SARS-CoV-2 mRNA vaccination series in 42 HSCT recipients and 5 healthy controls. Post-vaccination responses were assessed by anti-spike IgG and nucleocapsid levels, and antigen specific T cell activity. Immune profiling was performed using clinical flow and mass cytometry. Patients were selected based on humoral and cellular responses for single-cell RNA with TCR and BCR sequencing. Our studies revealed defects in memory T cells that correlated with an absence of cellular response despite nearly universal humoral response. Several patients with a robust antibody response developed COVID-19 infection, but none developed severe disease or died from the infection.

1 November 2021 in JAMA Oncology
Verified
Journal Article
Closed access
PDF file
LGLohith Gowda
Lohith Gowda
SSStuart E. Seropian
Stuart E. Seropian
Since its first application in 1957 between identical twins,1 the indications for allogeneic hematopoietic stem cell transplant have evolved substantially. Although the availability of a human leukocyte antigen–matched bone marrow graft from a sibling was considered essential in the early days of transplantation, advances in the techniques required to use alternative donors or perform transplantation in older recipients have expanded transplant access in the modern age to a far broader spectrum of patients. In the 1960s, the procedure was considered by some to be ethically questionable. In 2019, allogeneic hematopoietic stem cell transplant volumes in Europe and North America reached almost 30 000 cases.2 Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.

19 July 2018 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
TKTae Kon Kim
Tae Kon Kim
MDMichelle DeVeaux
Michelle DeVeaux
MSMaximilian Stahl
Maximilian Stahl
SPSarah Perreault
Sarah Perreault
IIIris Isufi
Iris Isufi
SSStuart E. Seropian
Stuart E. Seropian